Are Regulation and Innovation Priorities Serving Public Health Needs?
A host of challenges confront healthcare authorities worldwide. Topping the list is the demand for innovative new medicines to treat a range of both infectious and non-communicable diseases, while containing spiraling healthcare costs. The challenge is particularly great in therapeutic areas where,...
Main Authors: | Christopher-Paul Milne, Kenneth I. Kaitin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00144/full |
Similar Items
-
Comparative Analysis of the QbD Approach in the Pharmaceutical Industry
by: S. A. Rozhnova, et al.
Published: (2019-11-01) -
FEATURES OF THE INNOVATION PROCESS AT THE UKRAINIAN PHARMACEUTICAL ENTERPRISES
by: O. Chulak
Published: (2013-03-01) -
Public Support Agencies for Innovation in Multilevel Governance Systems: Exploring the Existence of Signs of Complementarity and Substitution
by: Jennifer González-Blanco, et al.
Published: (2019-10-01) -
Emergence of Enhanced Quality Expectations in Pharmaceuticals
by: Roohi Bano Obaid, et al.
Published: (2018-09-01) -
Efficiency of Public R&D Management Agency and Its Improvement toward Open Innovation
by: Byung-Yong Hwang, et al.
Published: (2021-09-01)